3 Works

Data from: Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420

Nicolas Blondiaux, Martin Moune, Matthieu Desroses, Rosangela Frita, Marion Flipo, Vanessa Mathys, Karine Soetaert, Mehdi Kiass, Vincent Delorme, Kamel Djaout, Vincent Trebosc, Christian Kemmer, René Wintjens, Alexandre Wohlkönig, Rudy Antoine, Ludovic Huot, David Hot, Mireia Coscolla, Julia Feldmann, Sebastien Gagneux, Camille Locht, Priscille Brodin, Marc Gitzinger, Benoit Deprez, Nicolas Willand … & Alain R. Baulard
Antibiotic resistance is one of the biggest threats to human health globally. Alarmingly, multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis have now spread worldwide. Some key antituberculosis antibiotics are prodrugs, for which resistance mechanisms are mainly driven by mutations in the bacterial enzymatic pathway required for their bioactivation. We have developed drug-like molecules that activate a cryptic alternative bioactivation pathway of ethionamide in M. tuberculosis, circumventing the classic activation pathway in which resistance mutations have now...

Data from: Mutator genomes decay, despite sustained fitness gains, in a long-term experiment with bacteria

Alejandro Couce, Larissa Viraphong Caudwell, Christoph Feinauer, Thomas Hindré, Jean-Paul Feugeas, Martin Weigt, Richard E. Lenski, Dominique Schneider & Olivier Tenaillon
Understanding the extreme variation among bacterial genomes remains an unsolved challenge in evolutionary biology, despite long-standing debate about the relative importance of natural selection, mutation, and random drift. A potentially important confounding factor is the variation in mutation rates between lineages and over evolutionary history, which has been documented in several species. Mutation accumulation experiments have shown that hypermutability can erode genomes over short timescales. These results, however, were obtained under conditions of extremely weak...

Data from: Screening test for neutralizing antibodies against yellow fever virus, based on a flavivirus pseudotype

Séverine Mercier-Delarue, Christine Durier, Nathalie Colin De Verdière, Jean-Dominique Poveda, VIncent Meiffrédy, Maria Dolores Fernandez Garcia, Stephane Lastère, Raymond Césaire, Jean-Claude Manuggera, Jean-Michel Molina, Ali Amara & François Simon
Given the possibility of yellow fever virus reintroduction in epidemiologically receptive geographic areas, the risk of vaccine supply disruption is a serious issue. New strategies to reduce the doses of injected vaccines should be evaluated very carefully in terms of immunogenicity. The plaque reduction test for the determination of neutralizing antibodies (PRNT) is particularly time-consuming and requires the use of a confinement laboratory. We have developed a new test based on the use of a...

Registration Year

  • 2017
    3

Resource Types

  • Dataset
    3

Affiliations

  • Inserm
    3
  • Université Libre de Bruxelles
    1
  • Saint Louis University Hospital
    1
  • University of Lille
    1
  • Techniques for Biomedical Engineering and Complexity Management–Informatics, Mathematics and Applications Grenoble
    1
  • Swiss Tropical and Public Health Institute
    1
  • Flanders Institute for Biotechnology
    1
  • Institut Pasteur
    1
  • Institut Scientifique de Santé Publique
    1
  • Michigan State University
    1